Modafinil in the treatment of excessive daytime sleepiness

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 8, 2007, Pages 561-571

  Valentino, Roxanne M ^a   Foldvary Schaefer, Nancy ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Section of Sleep Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; MODAFINIL;

ATTENTION DEFICIT DISORDER; DRUG INTERACTION; HUMAN; MULTIPLE SCLEROSIS; NARCOLEPSY; PARKINSON DISEASE; POSITIVE END EXPIRATORY PRESSURE; REVIEW; SLEEP APNEA SYNDROME; SOMNOLENCE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONTINUOUS POSITIVE AIRWAY PRESSURE; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG INTERACTIONS; HUMANS; MULTIPLE SCLEROSIS; NARCOLEPSY; PARKINSON DISEASE; SLEEP APNEA, OBSTRUCTIVE;

EID: 35248826574     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.8.561     Document Type: Review

References (50)

1. Provigil marketing data. Cephalon Inc., 2004.
2. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20:8620-8628.
3. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996; 93:14128-14133.
4. Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004; 27:19-25.
5. Mignot E, Nishino S, Guilleminault C, Dement WS. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17:436-437.
6. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21:1787-1794.
7. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42:123-137.
8. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-545.
9. Littner MR, Kushida C, Wise M, et al; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005; 28:113-121.
10. Aldrich MS, Chervin RD, Mallow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997; 20:620-629.
11. American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic and coding manual, 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
12. US Modafinill in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43:88-97.
13. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: Neurology 2000; 54:1166-1175.
14. Schwartz JR, Nelson MT, Schwartz ER, Hughes RJ. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 2004; 27:74-79.
15. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993; 16:46-53.
16. Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991; 14:218-220.
17. Xyrem prescribing information. Jazz Pharmaceuticals, Inc.
18. US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25:42-49.
19. US Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26:31-35.
20. Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:1675-1681.
21. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005; 28:464-471.
22. Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 112-week, open-label study. Chest 2003; 124:2192-2199.
23. Bureau of Labor Statistics. Workers on flexible and shift schedules in 2004. www.bls.gov/news.release/flex.nr0.htm.
24. Torsvall L, Akerstedt T, Gillander K, Knutsson A. Sleep on the night shift: 24-hour EEG monitoring of spontaneous sleep/wake behavior. Psychophysiology 1989; 26:352-358.
25. Czeisler CA, Walsh JK, Roth T, et al; US Modafinil in Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005; 353:476-486.
26. Walsh JK, Randazzo AC, Stone KL, Schweitzer PK. Modafinil improves alertness, vigilance, and executive function during simulated night shifts. Sleep 2004; 27:434-439.
27. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988; 45:435-437.
28. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46:1121-1123.
29. Schwild SR, Covington M, Segal BM, Goodman AD. Fatigue in multiple sclerosis: current understanding and future directions. J Rehabil Res Dev 2002; 39:211-224.
30. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72:179-183.
31. Dowson A, Kilminster S, Salt R. Provigil: a pilot, single-centre, double-blind, placebo-controlled crossover study in the treatment of fatigue in multiple sclerosis [abstract]. Presented at the 12th meeting of the European Neurological Society, June 22-26, 2002, Berlin, Germany.
32. Stankoff B, Waubant E. Confavreux C, et al. Efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind multicenter study [abstract]. Presented at the 13th meeting of the European Neurological Society, June 14-18, 2003, Istanbul, Turkey.
33. Pary R, Lewis S, Matuschka PR, Rudzinskiy P, Safi M, Lippmann S. Attention deficit disorder in adults. Ann Clin Psychiatry 2002; 14:105-111.
34. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10:311-320.
35. Turner DC, Clark L, Dowson J, et al. Modafinil and adult ADHD: effects of a novel cognitive enhancer [abstract]. Presented at the British Association for Psychopharmacology. 2003; 17:A78.
36. Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol 2GO3; 29:136-142.
37. Partinen M. Sleep disorder related to Parkinson's disease. J Neurol 1997; 244(suppl 1):S3-6.
38. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990; 5:280-285.
39. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18:287-293.
40. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60:221-225.
41. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR; Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64:1057-1064.
42. Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 2004; 65:414-420.
43. Randall DC, Cafferty FH, Shneerson JM, Smith IE, Llewellyn MB, File SE. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005; 19:647-660.
44. Akashiba T, Kawahara S, Akahoshi T, et al. Relationship between quality of life and mood or depression in patients with severe obstructive sleep apnea syndrome. Chest 2002; 122:861-865.
45. Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 2003; 4:393-402.
46. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995; 18:817-826.
47. Data on file. Cephalon, Inc.
48. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry 2004; 16:101-109.
49. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 2002; 13:105-115.
50. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000; 23:149-156.